Navigation Links
Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/6/2009

to justify development and commercialization costs if our products are approved for marketing; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; reliance on third parties to manufacture, market and distribute many of our products; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in ongoing or future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this press release to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements.

SVNT-I

                SAVIENT PHARMACEUTICALS, INC. AND SUBSIDIARIES
                        CONSOLIDATED BALANCE SHEETS
                              (Unaudited)
                     (In thousands, except share data)


                                                   March 31,     December 31,
                 
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Submits Biologics License Application (BLA) for pegloticase
4. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
6. Savient Announces Appointment of David Gionco as Chief Financial Officer
7. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
8. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/22/2014)... RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a ... of autologous cell therapies, announced today the publication of ... conjunction with co-authors from Kyoto University and the University ... clinical research using dermal sheath cup (DSC) cells to ... paper entitled " Hair Follicle Dermal Stem Cells Regenerate ...
(Date:12/22/2014)... 2014 ITRA Global, one of the ... commercial real estate, has further expanded its global reach ... and Brisbane, Western Australia, reports Mylinda Vick, CCIM, Chairman ... ITRA Global / ACORPP (Australian Corporate Property and Projects) ... providing property services to a wide range of clients ...
(Date:12/19/2014)... Dec. 19, 2014 Naurex Inc., a biopharmaceutical ... for diseases of the central nervous system, today announced ... executive officer, will present at the 33 rd ... take place at 3:00 p.m. PST on Tuesday, January ... San Francisco, Calif. ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... , BRUSSELS , June 18 ... system) significantly improved wellbeing and daily activities that are often ... presented this week at the 14th International Congress of Parkinson,s ... Additional data from an open-label extension study showed that the ...
... NATICK, Massachusetts and NICE, France , ... BSX ) today,announced results from a sub-analysis ... greater clinical benefit from its cardiac resynchronization,therapy defibrillators (CRT-Ds) ... World Congress by Jonathan Steinberg , M.D., Chief ...
... of water mysteriously gush out of the desert floor at a ... plant and animal species found nowhere else in the world. ... at Ash Meadows is completing a 15,000-year journey, flowing slowly underground ... government tested nuclear bombs there for four decades, and a crack ...
Cached Biology Technology:Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 2Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 3Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 4Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 5Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 6Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 7Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 8Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 9Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 10MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men 2MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men 3MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men 4
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... take-away paper-based food containers (such as pizza boxes) that ... because the containers were made from pulp that contained ... where the test was developed, this use of recycled ... rules. Recycling paper and cardboard is a great ...
... Fingerprint Software Enhances Biometric Time Clock Security ... Fingerprint SDK Development, ATLANTA, Nov. 27 ... firm, announced today that Software,Techniques Inc. has ... by integrating M2SYS, Bio-SnapON(TM) solution., Bio-SnapON(TM) ...
... Scientists Meet for Global Conference ,On Stem Cell ... Ground-breaking Advances, Pioneering Innovations ,In Cell-Based Therapeutic Approaches ... Research Foundation (CRF) brings experts to New York ... Annual International Conference on Cell Therapy for Cardiovascular ...
Cached Biology News:New test finds diisobutyl phthalate in some cardboard food packaging -- recycling is the issue 2Software Techniques Inc. Selects M2SYS Fingerprint Software to Meet Continuous Growth and Demand for Desktop Biometric Time & Attendance Solutions 2Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases 2Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases 3
Compact, portable device, seals 96 and 384 well plates with preset temperature optimised for Eppendorf heat sealing foils and films. Suitable for plates of different heights. AC input: 50/60 Hz230 V...
Volume adapter mounts on top of the 96 well FiltrEX filter plate and allows larger volumes (1mL) to be applied to each well in a filter plate. Adapters are nonsterile....
Rabbit polyclonal to ErbB 2 (phospho Y1248) ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
... multi-casting chamber is used for handcasting and vertical ... (8.3 x 7.3 cm) or precast (8.6 x ... of buffer and includes an electrophoresis tank with ... refrigerated circulator (not included), lid with power cables, ...
Biology Products: